Immune adjuvant effect of molecularly-defined Toll-like receptor ligands

Vaccines

Volumn 2, Issue 2, 2014, Pages 323-353

  Toussi, Deana N ^a   Massari, Paola ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Immune response; Microbial pathogens; TLR; Vaccine adjuvant

Indexed keywords

HEPATITIS B VACCINE; HILTONOL; LYME DISEASE VACCINE; MELACINE; PATTERN RECOGNITION RECEPTOR; PHOSPHORYL LIPID A; RINTATOLIMOD; TECEMOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; DENDRITIC CELL; DIMERIZATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VACCINATION;

EID: 85019440984     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2020323     Document Type: Review

References (229)

1. Gupta, R. K.; Relyveld, E. H.; Lindblad, E. B.; Bizzini, B.; Efraim, S. B.; Gupta, C. K. Adjuvants-A balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293-306.
2. Singh, M.; Srivastava, I. Advances in vaccine adjuvants for infectious diseases. Curr. HIV. Res. 2003, 1, 309-320.
3. Guy, B. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5, 505-517.
4. Glenny, A. T. Immunological notes: Antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 1926, 29, 38-39.
5. Freund, J. The mode of action of immunologic adjuvants. Bibl. Tuberc. 1956, 10, 130-148.
6. Calabro, S.; Tritto, E.; Pezzotti, A.; Taccone, M.; Muzzi, A.; Bertholet, S.; de Gregorio, E.; O'Hagan, D. T.; Baudner, B.; Seubert, A. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31, 3363-3369.
7. Hutchison, S.; Benson, R. A.; Gibson, V. B.; Pollock, A. H.; Garside, P.; Brewer, J. M. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012, 26, 1272-1279.
8. Seubert, A.; Calabro, S.; Santini, L.; Galli, B.; Genovese, A.; Valentini, S.; Aprea, S.; Colaprico, A.; D'Oro, U.; Giuliani, M. M.; et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. USA 2011, 108, 11169-11174.
9. Janeway, C. A., Jr. Immunogenecity: Signal 1, 2, 3. and 0. Immunol. Today 1989, 10, 283-287.
10. Awate, S.; Babiuk, L. A.; Mutwiri, G. Mechanisms of action of adjuvants. Front. Immunol. 2013, 4, doi: 10. 3389/fimmu. 2013. 00114.
11. Mosmann, T. R.; Cherwinski, H. M.; Bond, M. W.; Giedlin, M. A.; Coffman, R. L. Two types of murine helper T cell clones. I. Definition according to the profiles of lymphokine activity and secreted proteins. J. Immunol. 1986, 136, 2348-2357.
12. Harrington, L. E.; Mangan, P. R.; Weaver, C. T. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr. Opin. Immunol. 2006, 18, 349-356.
13. Ouyang, W.; Kolls, J. K.; Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28, 454-467.
14. Buck, S. B.; Bradford, J.; Gee, K. R.; Agnew, B. J.; Clarke, S. T.; Salic, A. Detection of S-phase cell cycle progression using 5-ethynyl-2'-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2'-deoxyuridine antibodies. Biotechniques 2008, 44, 927-929.
15. Kumar, P.; Chen, K.; Kolls, J. K. Th17 cell based vaccines in mucosal immunity. Curr. Opin. Immunol. 2013, 25, 373-380.
16. Brewer, J. M.; Conacher, M.; Hunter, C. A.; Mohrs, M.; Brombacher, F.; Alexander, J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J. Immunol. 1999, 163, 6448-6454.
17. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C. A., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388, 394-397.
18. Kaisho, T.; Akira, S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 2002, 1589, 1-13.
19. Duthie, M. S.; Windish, H. P.; Fox, C. B.; Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 2011, 239, 178-196.
20. Gnjatic, S.; Sawhney, N. B.; Bhardwaj, N. Toll-like receptor agonists: Are they good adjuvants? Cancer J. 2010, 16, 382-391.
21. Jin, B.; Sun, T.; Yu, X. H.; Yang, Y. X.; Yeo, A. E. The effects of TLR activation on T-cell development and differentiation. Clin. Dev. Immunol. 2012, 2012,. doi: 10. 1155/2012/836485.
22. Conroy, H.; Marshall, N. A.; Mills, K. H. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008, 27, 168-180.
23. Keijzer, C.; van der Zee, R.; van, E. W.; Broere, F. Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases. Front. Immunol. 2013, 4, doi: 10. 3389/fimmu. 2013. 00245.
24. Akira, S.; Hemmi, H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 2003, 85, 85-95.
25. Cario, E.; Brown, D.; McKee, M.; Lynch-Devaney, K.; Gerken, G.; Podolsky, D. K. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am. J. Pathol. 2002, 160, 165-173.
26. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12, 991-1045.
27. Medzhitov, R.; Preston-Hurlburt, P.; Kopp, E.; Stadlen, A.; Chen, C.; Ghosh, S.; Janeway, C. A., Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell. 1998, 2, 253-258.
28. Fitzgerald, K. A.; Palsson-McDermott, E. M.; Bowie, A. G.; Jefferies, C. A.; Mansell, A. S.; Brady, G.; Brint, E.; Dunne, A.; Gray, P.; Harte, M. T.; et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001, 413, 78-83.
29. Fitzgerald, K. A.; Rowe, D. C.; Barnes, B. J.; Caffrey, D. R.; Visintin, A.; Latz, E.; Monks, B.; Pitha, P. M.; Golenbock, D. T. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the toll adapters TRAM and TRIF. J. Exp. Med. 2003, 198, 1043-1055.
30. O'Neill, L. A.; Fitzgerald, K. A.; Bowie, A. G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 2003, 24, 286-289.
31. Muzio, M.; Ni, J.; Feng, P.; Dixit, V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278, 1612-1615.
32. Gohda, J.; Matsumura, T.; Inoue, J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling. J. Immunol. 2004, 173, 2913-2917.
33. Meylan, E.; Burns, K.; Hofmann, K.; Blancheteau, V.; Martinon, F.; Kelliher, M.; Tschopp, J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 2004, 5, 503-507.
34. Shim, J. H.; Xiao, C.; Paschal, A. E.; Bailey, S. T.; Rao, P.; Hayden, M. S.; Lee, K. Y.; Bussey, C.; Steckel, M.; Tanaka, N.; et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005, 19, 2668-2681.
35. Honda, K.; Yanai, H.; Negishi, H.; Asagiri, M.; Sato, M.; Mizutani, T.; Shimada, N.; Ohba, Y.; Takaoka, A.; Yoshida, N.; et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434, 772-777.
36. Oganesyan, G.; Saha, S. K.; Guo, B.; He, J. Q.; Shahangian, A.; Zarnegar, B.; Perry, A.; Cheng, G. Critical role of TRAF3 in the Toll-like receptor-dependent and-independent antiviral response. Nature 2006, 439, 208-211.
37. Muzio, M.; Polentarutti, N.; Bosisio, D.; Prahladan, M. K.; Mantovani, A. Toll-like receptors: A growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J. Leukoc. Biol. 2000, 67, 450-456.
38. Liu, L.; Botos, I.; Wang, Y.; Leonard, J. N.; Shiloach, J.; Segal, D. M.; Davies, D. R. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008, 320, 379-381.
39. Alexopoulou, L.; Holt, A. C.; Medzhitov, R.; Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413, 732-738.
40. Matsukura, S.; Kokubu, F.; Kurokawa, M.; Kawaguchi, M.; Ieki, K.; Kuga, H.; Odaka, M.; Suzuki, S.; Watanabe, S.; Homma, T.; et al. Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int. Arch. Allergy Immunol. 2007, 143, 80-83.
41. Salem, M. L.; Diaz-Montero, C. M.; El-Naggar, S. A.; Chen, Y.; Moussa, O.; Cole, D. J. The TLR3 agonist poly(I: C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice. Vaccine 2009, 27, 549-557.
42. Nordlund, J. J.; Wolff, S. M.; Levy, H. B. Inhibition of biologic activity of poly I: poly C by human plasma. Proc. Soc. Exp. Biol. Med. 1970, 133, 439-444.
43. Schulz, O.; Diebold, S. S.; Chen, M.; Naslund, T. I.; Nolte, M. A.; Alexopoulou, L.; Azuma, Y. T.; Flavell, R. A.; Liljestrom, P.; e Sousa, C. R. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433, 887-892.
44. Fujimoto, C.; Nakagawa, Y.; Ohara, K.; Takahashi, H. Polyriboinosinic polyribocytidylic acid [poly(I: C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int. Immunol. 2004, 16, 55-63.
45. Trumpfheller, C.; Caskey, M.; Nchinda, G.; Longhi, M. P.; Mizenina, O.; Huang, Y.; Schlesinger, S. J.; Colonna, M.; Steinman, R. M. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. USA 2008, 105, 2574-2579.
46. Scallan, C. D.; Tingley, D. W.; Lindbloom, J. D.; Toomey, J. S.; Tucker, S. N. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin. Vaccine Immunol. 2013, 20, 85-94.
47. Pulko, V.; Liu, X.; Krco, C. J.; Harris, K. J.; Frigola, X.; Kwon, E. D.; Dong, H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J. Immunol. 2009, 183, 3634-3641.
48. Krown, S. E.; Kerr, D.; Stewart, W. E.; Field, A. K.; Oettgen, H. F. Phase I trials of poly(I, C) complexes in advanced cancer. J. Biol. Response Mod. 1985, 4, 640-649.
49. Levy, H. B.; Baer, G.; Baron, S.; Buckler, C. E.; Gibbs, C. J.; Iadarola, M. J.; London, W. T.; Rice, J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132, 434-439.
50. Butowski, N.; Chang, S. M.; Junck, L.; DeAngelis, L. M.; Abrey, L.; Fink, K.; Cloughesy, T.; Lamborn, K. R.; Salazar, A. M.; Prados, M. D. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: A North American Brain Tumor Consortium (NABTC01-05). J. Neurooncol. 2009, 91, 175-182.
51. Stahl-Hennig, C.; Eisenblatter, M.; Jasny, E.; Rzehak, T.; Tenner-Racz, K.; Trumpfheller, C.; Salazar, A. M.; Uberla, K.; Nieto, K.; Kleinschmidt, J.; et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS. Pathog. 2009, 5, e1000373.
52. Gram, G. J.; Karlsson, I.; Agger, E. M.; Andersen, P.; Fomsgaard, A. A novel liposome-based adjuvant CAF01 for induction of CD8+ cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One 2009, 4, e6950.
53. Ichinohe, T.; Kawaguchi, A.; Tamura, S.; Takahashi, H.; Sawa, H.; Ninomiya, A.; Imai, M.; Itamura, S.; Odagiri, T.; Tashiro, M.; et al. Intranasal immunization with H5N1 vaccine plus Poly I: Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect. 2007, 9, 1333-1340.
54. Adams, M.; Navabi, H.; Jasani, B.; Man, S.; Fiander, A.; Evans, A. S.; Donninger, C.; Mason, M. Dendritic cell (DC) based therapy for cervical cancer: Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C(12)U] (Ampligen R). Vaccine 2003, 21, 787-790.
55. Dupont, J.; Altclas, J.; Lepetic, A.; Lombardo, M.; Vazquez, V.; Salgueira, C.; Seigelchifer, M.; Arndtz, N.; Antunez, E.; von Eschen, K.; et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 2006, 24, 7167-7174.
56. Tielemans, C. L.; Vlasak, J.; Kosa, D.; Billiouw, J. M.; Verpooten, G. A.; Mezei, I.; Ryba, M.; Peeters, P. C.; Mat, O.; Jadoul, M. Y.; et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011, 29, 1159-1166.
57. Kundi, M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 2007, 6, 133-140.
58. Thoelen, S.; de Clercq, N.; Tornieporth, N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001, 19, 2400-2403.
59. Tong, N. K.; Beran, J.; Kee, S. A.; Miguel, J. L.; Sanchez, C.; Bayas, J. M.; Vilella, A.; de Juanes, J. R.; Arrazola, P.; Calbo-Torrecillas, F.; et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005, 68, 2298-2303.
60. Nascimento, E.; Fernandes, D. F.; Vieira, E. P.; Campos-Neto, A.; Ashman, J. A.; Alves, F. P.; Coler, R. N.; Bogatzki, L. Y.; Kahn, S. J.; Beckmann, A. M.; et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010, 28, 6581-6587.
61. Kathaperumal, K.; Park, S. U.; McDonough, S.; Stehman, S.; Akey, B.; Huntley, J.; Wong, S.; Chang, C. F.; Chang, Y. F. Vaccination with recombinant Mycobacterium avium subsp. paratuberculosis proteins induces differential immune responses and protects calves against infection by oral challenge. Vaccine 2008, 26, 1652-1663.
62. Spertini, F.; Audran, R.; Lurati, F.; Ofori-Anyinam, O.; Zysset, F.; Vandepapeliere, P.; Moris, P.; Demoitie, M. A.; Mettens, P.; Vinals, C.; et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study. Tuberculosis 2013, 93, 179-188.
63. Lal, H.; Zahaf, T.; Heineman, T. C. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults. Hum. Vaccin. Immunother. 2013, 9, 1425-1429.
64. Pichyangkul, S.; Gettayacamin, M.; Miller, R. S.; Lyon, J. A.; Angov, E.; Tongtawe, P.; Ruble, D. L.; Heppner, D. G., Jr.; Kester, K. E.; Ballou, W. R.; et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 2004, 22, 3831-3840.
65. Alonso, P. L.; Sacarlal, J.; Aponte, J. J.; Leach, A.; Macete, E.; Aide, P.; Sigauque, B.; Milman, J.; Mandomando, I.; Bassat, Q.; et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366, 2012-2018.
66. Agnandji, S. T.; Lell, B.; Soulanoudjingar, S. S.; Fernandes, J. F.; Abossolo, B. P.; Conzelmann, C.; Methogo, B. G.; Doucka, Y.; Flamen, A.; Mordmuller, B.; et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365, 1863-1875.
67. Bojang, K.; Milligan, P.; Pinder, M.; Doherty, T.; Leach, A.; Ofori-Anyinam, O.; Lievens, M.; Kester, K.; Schaecher, K.; Ballou, W. R.; et al. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS, S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum. Vaccin. 2009, 5, 242-247.
68. Moore, A.; McCarthy, L.; Mills, K. H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999, 17, 2517-2527.
69. Leroux-Roels, I.; Koutsoukos, M.; Clement, F.; Steyaert, S.; Janssens, M.; Bourguignon, P.; Cohen, K.; Altfeld, M.; Vandepapeliere, P.; Pedneault, L.; et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 2010, 28, 7016-7024.
70. Paavonen, J.; Naud, P.; Salmeron, J.; Wheeler, C. M.; Chow, S. N.; Apter, D.; Kitchener, H.; Castellsague, X.; Teixeira, J. C.; Skinner, S. R.; et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009, 374, 301-314.
71. Bhatla, N.; Suri, V.; Basu, P.; Shastri, S.; Datta, S. K.; Bi, D.; Descamps, D. J.; Bock, H. L. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J. Obstet. Gynaecol. Res. 2010, 36, 123-132.
72. Romanowski, B.; de Borba, P. C.; Naud, P. S.; Roteli-Martins, C. M.; de Carvalho, N. S.; Teixeira, J. C.; Aoki, F.; Ramjattan, B.; Shier, R. M.; Somani, R.; et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6. 4 years. Lancet 2009, 374, 1975-1985.
73. Sow, P. S.; Watson-Jones, D.; Kiviat, N.; Changalucha, J.; Mbaye, K. D.; Brown, J.; Bousso, K.; Kavishe, B.; Andreasen, A.; Toure, M.; et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: A randomized trial in 10-25-year-old HIV-seronegative African girls and young women. J. Infect. Dis. 2013, 207, 1753-1763.
74. Stanberry, L. R.; Spruance, S. L.; Cunningham, A. L.; Bernstein, D. I.; Mindel, A.; Sacks, S.; Tyring, S.; Aoki, F. Y.; Slaoui, M.; Denis, M.; et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002, 347, 1652-1661.
75. Sokal, E. M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Leonard, P.; Moreels, A.; Haumont, M.; Bollen, A.; Smets, F.; Denis, M. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 2007, 196, 1749-1753.
76. Sondak, V. K.; Sosman, J. A. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin. Cancer Biol. 2003, 13, 409-415.
77. Brichard, V. G.; Lejeune, D. GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 2007, 25, B61-B71.
78. North, S.; Butts, C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines 2005, 4, 249-257.
79. Holmberg, L. A.; Sandmaier, B. M. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 2004, 3, 655-663.
80. Isambert, N.; Fumoleau, P.; Paul, C.; Ferrand, C.; Zanetta, S.; Bauer, J.; Ragot, K.; Lizard, G.; Jeannin, J. F.; Bardou, M. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 2013, 13, e172.
81. Johnson, D. A.; Sowell, C. G.; Johnson, C. L.; Livesay, M. T.; Keegan, D. S.; Rhodes, M. J.; Ulrich, J. T.; Ward, J. R.; Cantrell, J. L.; Brookshire, V. G. Synthesis and biological evaluation of a new class of vaccine adjuvants: Aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. 1999, 9, 2273-2278.
82. Treanor, J. J.; Essink, B.; Hull, S.; Reed, S.; Izikson, R.; Patriarca, P.; Goldenthal, K. L.; Kohberger, R.; Dunkle, L. M. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 2013, 31, 5760-5765.
83. Schulze, H. J.; Cribier, B.; Requena, L.; Reifenberger, J.; Ferrandiz, C.; Garcia, D. A.; Tebbs, V.; McRae, S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle-controlled phase III study in Europe. Br. J. Dermatol. 2005, 152, 939-947.
84. Lebwohl, M.; Dinehart, S.; Whiting, D.; Lee, P. K.; Tawfik, N.; Jorizzo, J.; Lee, J. H.; Fox, T. L. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 2004, 50, 714-721.
85. Feyerabend, S.; Stevanovic, S.; Gouttefangeas, C.; Wernet, D.; Hennenlotter, J.; Bedke, J.; Dietz, K.; Pascolo, S.; Kuczyk, M.; Rammensee, H. G.; et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009, 69, 917-927.
86. Smorlesi, A.; Papalini, F.; Orlando, F.; Donnini, A.; Re, F.; Provinciali, M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 2005, 12, 1324-1332.
87. Adams, S.; O'Neill, D. W.; Nonaka, D.; Hardin, E.; Chiriboga, L.; Siu, K.; Cruz, C. M.; Angiulli, A.; Angiulli, F.; Ritter, E.; et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 2008, 181, 776-784.
88. Wille-Reece, U.; Flynn, B. J.; Lore, K.; Koup, R. A.; Kedl, R. M.; Mattapallil, J. J.; Weiss, W. R.; Roederer, M.; Seder, R. A. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 2005, 102, 15190-15194.
89. Arevalo, I.; Ward, B.; Miller, R.; Meng, T. C.; Najar, E.; Alvarez, E.; Matlashewski, G.; Llanos-Cuentas, A. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 2001, 33, 1847-1851.
90. Tougan, T.; Aoshi, T.; Coban, C.; Katakai, Y.; Kai, C.; Yasutomi, Y.; Ishii, K. J.; Horii, T. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. Hum. Vaccin. Immunother. 2013, 9, 283-290.
91. Ellis, R. D.; Martin, L. B.; Shaffer, D.; Long, C. A.; Miura, K.; Fay, M. P.; Narum, D. L.; Zhu, D.; Mullen, G. E.; Mahanty, S.; et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 2010, 5, e8787.
92. Ellis, R. D.; Wu, Y.; Martin, L. B.; Shaffer, D.; Miura, K.; Aebig, J.; Orcutt, A.; Rausch, K.; Zhu, D.; Mogensen, A.; et al. Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against P. falciparum malaria. PLoS One 2012, 7, e46094.
93. Cooper, C. L.; Davis, H. L.; Morris, M. L.; Efler, S. M.; Krieg, A. M.; Li, Y.; Laframboise, C.; al Adhami, M. J.; Khaliq, Y.; Seguin, I.; et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22, 3136-3143.
94. Payette, P. J.; Ma, X.; Weeratna, R. D.; McCluskie, M. J.; Shapiro, M.; Engle, R. E.; Davis, H. L.; Purcell, R. H. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. Intervirology 2006, 49, 144-151.
95. Halperin, S. A.; van Nest, G.; Smith, B.; Abtahi, S.; Whiley, H.; Eiden, J. J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21, 2461-2467.
96. Halperin, S. A.; McNeil, S.; Langley, J. M.; Smith, B.; MacKinnon-Cameron, D.; McCall-Sani, R.; Heyward, W. L.; Martin, J. T. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012, 30, 5445-5448.
97. Sablan, B. P.; Kim, D. J.; Barzaga, N. G.; Chow, W. C.; Cho, M.; Ahn, S. H.; Hwang, S. G.; Lee, J. H.; Namini, H.; Heyward, W. L. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30, 2689-2696.
98. Hopkins, R. J.; Daczkowski, N. F.; Kaptur, P. E.; Muse, D.; Sheldon, E.; LaForce, C.; Sari, S.; Rudge, T. L.; Bernton, E. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine 2013, 31, 3051-3058.
99. Wang, H. L.; Xu, H.; Lu, W. H.; Zhu, L.; Yu, Y. H.; Hong, F. Z. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch. Gynecol. Obstet. 2014, 289, 155-162.
100. Millward, M.; Underhill, C.; Lobb, S.; McBurnie, J.; Meech, S. J.; Gomez-Navarro, J.; Marshall, M. A.; Huang, B.; Mather, C. B. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br. J. Cancer 2013, 108, 1998-2004.
101. Karbach, J.; Neumann, A.; Atmaca, A.; Wahle, C.; Brand, K.; von Boehmer, L.; Knuth, A.; Bender, A.; Ritter, G.; Old, L. J.; et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 2011, 17, 861-870.
102. Hofmann, M. A.; Kors, C.; Audring, H.; Walden, P.; Sterry, W.; Trefzer, U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 2008, 31, 520-527.
103. Manegold, C.; Gravenor, D.; Woytowitz, D.; Mezger, J.; Hirsh, V.; Albert, G.; Al-Adhami, M.; Readett, D.; Krieg, A. M.; Leichman, C. G. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26, 3979-3986.
104. Speiser, D. E.; Schwarz, K.; Baumgaertner, P.; Manolova, V.; Devevre, E.; Sterry, W.; Walden, P.; Zippelius, A.; Conzett, K. B.; Senti, G.; et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J. Immunother. 2010, 33, 848-858.
105. Kruit, W. H.; Suciu, S.; Dreno, B.; Mortier, L.; Robert, C.; Chiarion-Sileni, V.; Maio, M.; Testori, A.; Dorval, T.; Grob, J. J.; et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 2013, 31, 2413-2420.
106. Cataldi, A.; Yevsa, T.; Vilte, D. A.; Schulze, K.; Castro-Parodi, M.; Larzabal, M.; Ibarra, C.; Mercado, E. C.; Guzman, C. A. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 2008, 26, 5662-5667.
107. Behrens, R. H.; Cramer, J. P.; Jelinek, T.; Shaw, H.; von, S. F.; Wilbraham, D.; Weinke, T.; Bell, D. J.; Asturias, E.; Pauwells, H. L.; et al. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: A phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect. Dis. 2013, 14, 197-204.
108. Steere, A. C.; Sikand, V. K.; Meurice, F.; Parenti, D. L.; Fikrig, E.; Schoen, R. T.; Nowakowski, J.; Schmid, C. H.; Laukamp, S.; Buscarino, C.; et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 1998, 339, 209-215.
109. Nigrovic, L. E.; Thompson, K. M. The Lyme vaccine: A cautionary tale. Epidemiol. Infect. 2007, 135, 1-8.
110. Nardin, E. H.; Calvo-Calle, J. M.; Oliveira, G. A.; Nussenzweig, R. S.; Schneider, M.; Tiercy, J. M.; Loutan, L.; Hochstrasser, D.; Rose, K. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 2001, 166, 481-489.
111. Lowell, G. H.; Ballou, W. R.; Smith, L. F.; Wirtz, R. A.; Zollinger, W. D.; Hockmeyer, W. T. Proteosome-lipopeptide vaccines: Enhancement of immunogenicity for malaria CS peptides. Science 1988, 240, 800-802.
112. Vitiello, A.; Ishioka, G.; Grey, H. M.; Rose, R.; Farness, P.; LaFond, R.; Yuan, L.; Chisari, F. V.; Furze, J.; Bartholomeuz, R. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 1995, 95, 341-349.
113. Livingston, B. D.; Crimi, C.; Fikes, J.; Chesnut, R. W.; Sidney, J.; Sette, A. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum. Immunol. 1999, 60, 1013-1017.
114. Durier, C.; Launay, O.; Meiffredy, V.; Saidi, Y.; Salmon, D.; Levy, Y.; Guillet, J. G.; Pialoux, G.; Aboulker, J. P. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006, 20, 1039-1049.
115. Neidleman, J. A.; Vajdy, M.; Ugozzoli, M.; Ott, G.; O'Hagan, D. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 2000, 101, 154-160.
116. Massari, P.; Toussi, D. N.; Tifrea, D. F.; de la Maza, L. M. Toll-Like receptor 2-dependent activity of native major outer membrane protein proteosomes of Chlamydia trachomatis. Infect. Immun. 2013, 81, 303-310.
117. Moreno-Eutimio, M. A.; Tenorio-Calvo, A.; Pastelin-Palacios, R.; Perez-Shibayama, C.; Gil-Cruz, C.; Lopez-Santiago, R.; Baeza, I.; Fernandez-Mora, M.; Bonifaz, L.; Isibasi, A.; et al. Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties. Immunology 2013, 139, 459-471.
118. Snapper, C. M.; Rosas, F. R.; Kehry, M. R.; Mond, J. J.; Wetzler, L. M. Neisserial porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion. Infect. Immun. 1997, 65, 3203-3208.
119. Mackinnon, F. G.; Ho, Y.; Blake, M. S.; Michon, F.; Chandraker, A.; Sayegh, M. H.; Wetzler, L. M. The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin. J. Infect. Dis. 1999, 180, 755-761.
120. Donnelly, J. J.; Deck, R. R.; Liu, M. A. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein vaccine. J. Immunol. 1990, 145, 3071-3079.
121. Fusco, P. C.; Michon, F.; Laude-Sharp, M.; Minetti, C. A.; Huang, C. H.; Heron, I.; Blake, M. S. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type B conjugate vaccine. Vaccine 1998, 16, 1842-1849.
122. Burke, J. M.; Ganley-Leal, L. M.; Khatri, A.; Wetzler, L. M. Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: Potential adjuvant for helminth vaccines? J. Immunol. 2007, 179, 3222-3230.
123. Chiavolini, D.; Weir, S.; Murphy, J. R.; Wetzler, L. M. Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia. Clin. Vaccine Immunol. 2008, 15, 1322-1329.
124. Mizel, S. B.; Graff, A. H.; Sriranganathan, N.; Ervin, S.; Lees, C. J.; Lively, M. O.; Hantgan, R. R.; Thomas, M. J.; Wood, J.; Bell, B. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin. Vaccine Immunol. 2009, 16, 21-28.
125. McDonald, W. F.; Huleatt, J. W.; Foellmer, H. G.; Hewitt, D.; Tang, J.; Desai, P.; Price, A.; Jacobs, A.; Takahashi, V. N.; Huang, Y.; et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 2007, 195, 1607-1617.
126. Hedayat, M.; Takeda, K.; Rezaei, N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med. Res. Rev. 2012, 32, 294-325.
127. Huleatt, J. W.; Jacobs, A. R.; Tang, J.; Desai, P.; Kopp, E. B.; Huang, Y.; Song, L.; Nakaar, V.; Powell, T. J. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25, 763-775.
128. Carapau, D.; Mitchell, R.; Nacer, A.; Shaw, A.; Othoro, C.; Frevert, U.; Nardin, E. Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin. Infect. Immun. 2013, 81, 4350-4362.
129. Sun, Y.; Shi, W.; Yang, J. Y.; Zhou, D. H.; Chen, Y. Q.; Zhang, Y.; Yang, Y.; He, B. X.; Zhong, M. H.; Li, Y. M.; et al. Flagellin-PAc fusion protein is a high-efficacy anti-caries mucosal vaccine. J. Dent. Res. 2012, 91, 941-947.
130. Jones, R. M.; Sloane, V. M.; Wu, H.; Luo, L.; Kumar, A.; Kumar, M. V.; Gewirtz, A. T.; Neish, A. S. Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut 2011, 60, 648-657.
131. Nguyen, C. T.; Hong, S. H.; Sin, J. I.; Vu, H. V.; Jeong, K.; Cho, K. O.; Uematsu, S.; Akira, S.; Lee, S. E.; Rhee, J. H. Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine 2013, 31, 3879-3887.
132. Skountzou, I.; Martin, M. P.; Wang, B.; Ye, L.; Koutsonanos, D.; Weldon, W.; Jacob, J.; Compans, R. W. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28, 4103-4112.
133. Hong, S. H.; Byun, Y. H.; Nguyen, C. T.; Kim, S. Y.; Seong, B. L.; Park, S.; Woo, G. J.; Yoon, Y.; Koh, J. T.; Fujihashi, K.; et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 2012, 30, 466-474.
134. Taylor, D. N.; Treanor, J. J.; Sheldon, E. A.; Johnson, C.; Umlauf, S.; Song, L.; Kavita, U.; Liu, G.; Tussey, L.; Ozer, K.; et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012, 30, 5761-5769.
135. Treanor, J. J.; Taylor, D. N.; Tussey, L.; Hay, C.; Nolan, C.; Fitzgerald, T.; Liu, G.; Kavita, U.; Song, L.; Dark, I.; et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28, 8268-8274.
136. Liu, G.; Tarbet, B.; Song, L.; Reiserova, L.; Weaver, B.; Chen, Y.; Li, H.; Hou, F.; Liu, X.; Parent, J.; et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS. One 2011, 6, e20928.
137. Talbot, H. K.; Rock, M. T.; Johnson, C.; Tussey, L.; Kavita, U.; Shanker, A.; Shaw, A. R.; Taylor, D. N. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010, 5, e14442.
138. Turley, C. B.; Rupp, R. E.; Johnson, C.; Taylor, D. N.; Wolfson, J.; Tussey, L.; Kavita, U.; Stanberry, L.; Shaw, A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2. 4xM2e) in healthy adults. Vaccine 2011, 29, 5145-5152.
139. Jasani, B.; Navabi, H.; Adams, M. Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009, 27, 3401-3404.
140. Christensen, D.; Foged, C.; Rosenkrands, I.; Lundberg, C. V.; Andersen, P.; Agger, E. M.; Nielsen, H. M. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int. J. Pharm. 2010, 390, 19-24.
141. Nordly, P.; Rose, F.; Christensen, D.; Nielsen, H. M.; Andersen, P.; Agger, E. M.; Foged, C. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I: C) incorporated into the CAF01 adjuvant via a double emulsion method. J. Control. Release 2011, 150, 307-317.
142. Dasari, P.; Nicholson, I. C.; Hodge, G.; Dandie, G. W.; Zola, H. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 2005, 236, 140-145.
143. Chow, J. C.; Young, D. W.; Golenbock, D. T.; Christ, W. J.; Gusovsky, F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 1999, 274, 10689-10692.
144. Tada, H.; Nemoto, E.; Shimauchi, H.; Watanabe, T.; Mikami, T.; Matsumoto, T.; Ohno, N.; Tamura, H.; Shibata, K.; Akashi, S.; et al. Saccharomyces cerevisiae-and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14-and Toll-like receptor 4-dependent manner. Microbiol. Immunol. 2002, 46, 503-512.
145. Kurt-Jones, E. A.; Popova, L.; Kwinn, L.; Haynes, L. M.; Jones, L. P.; Tripp, R. A.; Walsh, E. E.; Freeman, M. W.; Golenbock, D. T.; Anderson, L. J.; et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 2000, 1, 398-401.
146. Biragyn, A.; Ruffini, P. A.; Leifer, C. A.; Klyushnenkova, E.; Shakhov, A.; Chertov, O.; Shirakawa, A. K.; Farber, J. M.; Segal, D. M.; Oppenheim, J. J.; et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298, 1025-1029.
147. Peri, F.; Calabrese, V. Toll-like Receptor 4 (TLR4) modulation by synthetic and natural compounds: An update. J. Med. Chem. 2013, doi: 10. 1021/jm401006s.
148. Kim, H. M.; Park, B. S.; Kim, J. I.; Kim, S. E.; Lee, J.; Oh, S. C.; Enkhbayar, P.; Matsushima, N.; Lee, H.; Yoo, O. J.; et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007, 130, 906-917.
149. Schumann, R. R.; Leong, S. R.; Flaggs, G. W.; Gray, P. W.; Wright, S. D.; Mathison, J. C.; Tobias, P. S.; Ulevitch, R. J. Structure and function of lipopolysaccharide binding protein. Science 1990, 249, 1429-1431.
150. Latz, E.; Visintin, A.; Lien, E.; Fitzgerald, K. A.; Monks, B. G.; Kurt-Jones, E. A.; Golenbock, D. T.; Espevik, T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 2002, 277, 47834-47843.
151. Thompson, B. S.; Chilton, P. M.; Ward, J. R.; Evans, J. T.; Mitchell, T. C. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 2005, 78, 1273-1280.
152. Mata-Haro, V.; Cekic, C.; Martin, M.; Chilton, P. M.; Casella, C. R.; Mitchell, T. C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316, 1628-1632.
153. Garcon, N.; Chomez, P.; van Mechelen, M. GlaxoSmithKline adjuvant systems in vaccines: Concepts, achievements and perspectives. Expert Rev. Vaccines 2007, 6, 723-739.
154. Didierlaurent, A. M.; Morel, S.; Lockman, L.; Giannini, S. L.; Bisteau, M.; Carlsen, H.; Kielland, A.; Vosters, O.; Vanderheyde, N.; Schiavetti, F.; et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 2009, 183, 6186-6197.
155. Morefield, G. L.; Hawkins, L. D.; Ishizaka, S. T.; Kissner, T. L.; Ulrich, R. G. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 2007, 14, 1499-1504.
156. Gorden, K. B.; Gorski, K. S.; Gibson, S. J.; Kedl, R. M.; Kieper, W. C.; Qiu, X.; Tomai, M. A.; Alkan, S. S.; Vasilakos, J. P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 2005, 174, 1259-1268.
157. Ito, T.; Amakawa, R.; Kaisho, T.; Hemmi, H.; Tajima, K.; Uehira, K.; Ozaki, Y.; Tomizawa, H.; Akira, S.; Fukuhara, S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 2002, 195, 1507-1512.
158. Bishop, G. A.; Hsing, Y.; Hostager, B. S.; Jalukar, S. V.; Ramirez, L. M.; Tomai, M. A. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. 2000, 165, 5552-5557.
159. Hart, O. M.; Athie-Morales, V.; O'Connor, G. M.; Gardiner, C. M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol. 2005, 175, 1636-1642.
160. Peng, G.; Guo, Z.; Kiniwa, Y.; Voo, K. S.; Peng, W.; Fu, T.; Wang, D. Y.; Li, Y.; Wang, H. Y.; Wang, R. F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309, 1380-1384.
161. Heil, F.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Kirschning, C.; Akira, S.; Lipford, G.; Wagner, H.; Bauer, S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303, 1526-1529.
162. Jurk, M.; Heil, F.; Vollmer, J.; Schetter, C.; Krieg, A. M.; Wagner, H.; Lipford, G.; Bauer, S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3, doi: 10. 1038/ni0602-499.
163. Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; Jahrsdorfer, B.; Giese, T.; Endres, S.; Hartmann, G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168, 4531-4537.
164. Klinman, D. M.; Yi, A. K.; Beaucage, S. L.; Conover, J.; Krieg, A. M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 1996, 93, 2879-2883.
165. Overstreet, M. G.; Freyberger, H.; Cockburn, I. A.; Chen, Y. C.; Tse, S. W.; Zavala, F. CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells. Eur. J. Immunol. 2010, 40, 124-133.
166. Krug, A.; Towarowski, A.; Britsch, S.; Rothenfusser, S.; Hornung, V.; Bals, R.; Giese, T.; Engelmann, H.; Endres, S.; Krieg, A. M.; et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 2001, 31, 3026-3037.
167. Roman, M.; Martin-Orozco, E.; Goodman, J. S.; Nguyen, M. D.; Sato, Y.; Ronaghy, A.; Kornbluth, R. S.; Richman, D. D.; Carson, D. A.; Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 1997, 3, 849-854.
168. Bauer, S.; Kirschning, C. J.; Hacker, H.; Redecke, V.; Hausmann, S.; Akira, S.; Wagner, H.; Lipford, G. B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 2001, 98, 9237-9242.
169. Verthelyi, D.; Ishii, K. J.; Gursel, M.; Takeshita, F.; Klinman, D. M. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 2001, 166, 2372-2377.
170. Jurk, M.; Schulte, B.; Kritzler, A.; Noll, B.; Uhlmann, E.; Wader, T.; Schetter, C.; Krieg, A. M.; Vollmer, J. C-Class CpG ODN: Sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology 2004, 209, 141-154.
171. Verthelyi, D.; Klinman, D. M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 2003, 109, 64-71.
172. Shirota, H.; Klinman, D. M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev. Vaccines 2014, 13, 299-312.
173. Takeuchi, O.; Kawai, T.; Muhlradt, P. F.; Morr, M.; Radolf, J. D.; Zychlinsky, A.; Takeda, K.; Akira, S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 2001, 13, 933-940.
174. Takeuchi, O.; Sato, S.; Horiuchi, T.; Hoshino, K.; Takeda, K.; Dong, Z.; Modlin, R. L.; Akira, S. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 2002, 169, 10-14.
175. Hoebe, K.; Georgel, P.; Rutschmann, S.; Du, X.; Mudd, S.; Crozat, K.; Sovath, S.; Shamel, L.; Hartung, T.; Zahringer, U.; et al. CD36 is a sensor of diacylglycerides. Nature 2005, 433, 523-527.
176. Ranoa, D. R.; Kelley, S. L.; Tapping, R. I. Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J. Biol. Chem. 2013, 288, 9729-9741.
177. Buwitt-Beckmann, U.; Heine, H.; Wiesmuller, K. H.; Jung, G.; Brock, R.; Akira, S.; Ulmer, A. J. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur. J. Immunol. 2005, 35, 282-289.
178. Iwaki, D.; Mitsuzawa, H.; Murakami, S.; Sano, H.; Konishi, M.; Akino, T.; Kuroki, Y. The extracellular toll-like receptor 2 domain directly binds peptidoglycan derived from Staphylococcus aureus. J. Biol. Chem. 2002, 277, 24315-24320.
179. Tapping, R. I.; Tobias, P. S. Mycobacterial lipoarabinomannan mediates physical interactions between TLR1 and TLR2 to induce signaling. J. Endotoxin. Res. 2003, 9, 264-268.
180. Yadav, M.; Schorey, J. S. The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 2006, 108, 3168-3175.
181. Sato, M.; Sano, H.; Iwaki, D.; Kudo, K.; Konishi, M.; Takahashi, H.; Takahashi, T.; Imaizumi, H.; Asai, Y.; Kuroki, Y. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J. Immunol. 2003, 171, 417-425.
182. Barbalat, R.; Lau, L.; Locksley, R. M.; Barton, G. M. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat. Immunol. 2009, 10, 1200-1207.
183. Kirschning, C. J.; Schumann, R. R. TLR2: Cellular sensor for microbial and endogenous molecular patterns. Curr. Top. Microbiol Immunol. 2002, 270, 121-144.
184. Hajishengallis, G.; Tapping, R. I.; Harokopakis, E.; Nishiyama, S.; Ratti, P.; Schifferle, R. E.; Lyle, E. A.; Triantafilou, M.; Triantafilou, K.; Yoshimura, F. Differential interactions of fimbriae and lipopolysaccharide from Porphyromonas gingivalis with the Toll-like receptor 2-centred pattern recognition apparatus. Cell Microbiol. 2006, 8, 1557-1570.
185. Nair, S.; Ramaswamy, P. A.; Ghosh, S.; Joshi, D. C.; Pathak, N.; Siddiqui, I.; Sharma, P.; Hasnain, S. E.; Mande, S. C.; Mukhopadhyay, S. The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage. J. Immunol. 2009, 183, 6269-6281.
186. Jin, M. S.; Kim, S. E.; Heo, J. Y.; Lee, M. E.; Kim, H. M.; Paik, S. G.; Lee, H.; Lee, J. O. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130, 1071-1082.
187. Liang, S.; Hosur, K. B.; Lu, S.; Nawar, H. F.; Weber, B. R.; Tapping, R. I.; Connell, T. D.; Hajishengallis, G. Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer. J. Immunol. 2009, 182, 2978-2985.
188. Kattner, C.; Toussi, D. N.; Zaucha, J.; Wetzler, L. M.; Ruppel, N.; Zachariae, U.; Massari, P.; Tanabe, M. Crystallographic analysis of Neisseria meningitidis PorB extracellular loops potentially implicated in TLR2 recognition. J. Struct. Biol. 2013, 185, 440-447.
189. Chua, B. Y.; Olson, M. R.; Bedoui, S.; Sekiya, T.; Wong, C. Y.; Turner, S. J.; Jackson, D. C. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Immunol. Cell Biol. 2014, doi: 10. 1038/icb. 2013. 102.
190. DePaolo, R. W.; Kamdar, K.; Khakpour, S.; Sugiura, Y.; Wang, W.; Jabri, B. A specific role for TLR1 in protective T(H)17 immunity during mucosal infection. J. Exp. Med. 2012, 209, 1437-1444.
191. Prajeeth, C. K.; Jirmo, A. C.; Krishnaswamy, J. K.; Ebensen, T.; Guzman, C. A.; Weiss, S.; Constabel, H.; Schmidt, R. E.; Behrens, G. M. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur. J. Immunol. 2010, 40, 1272-1283.
192. Deprez, B.; Sauzet, J. P.; Boutillon, C.; Martinon, F.; Tartar, A.; Sergheraert, C.; Guillet, J. G.; Gomard, E.; Gras-Masse, H. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996, 14, 375-382.
193. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 2003, 67, 593-656.
194. Massari, P.; Visintin, A.; Gunawardana, J.; Halmen, K. A.; King, C. A.; Golenbock, D. T.; Wetzler, L. M. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J. Immunol. 2006, 176, 2373-2380.
195. Liu, X.; Wetzler, L. M.; Massari, P. The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant. Vaccine 2008, 26, 786-796.
196. Toussi, D. N.; Liu, X.; Massari, P. The fomA porin from Fusobacterium nucleatum is a toll-like receptor 2 agonist with immune adjuvant activity. Clin. Vaccine Immunol. 2012, 19, 1093-1101.
197. Ray, A.; Chatterjee, N. S.; Bhattacharya, S. K.; Biswas, T. Porin of Shigella dysenteriae enhances mRNA levels for Toll-like receptor 2 and MyD88, up-regulates CD80 of murine macrophage, and induces the release of interleukin-12. FEMS Immunol. Med. Microbiol. 2003, 39, 213-219.
198. Banerjee, P.; Biswas, A.; Biswas, T. Porin-incorporated liposome induces Toll-like receptors 2-and 6-dependent maturation and type 1 response of dendritic cell. Int. Immunol. 2008, 20, 1551-1563.
199. Wetzler, L. M.; Ho, Y.; Reiser, H. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. J. Exp. Med. 1996, 183, 1151-1159.
200. Platt, A.; Macleod, H.; Massari, P.; Liu, X.; Wetzler, L. In vivo and In vitro characterization of the immune stimulating activity of the Neisserial Porin PorB. PLoS One 2013, 8, e82171.
201. Livingston, P. O.; Calves, M. J.; Helling, F.; Zollinger, W. D.; Blake, M. S.; Lowell, G. H. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993, 11, 1199-1204.
202. Spangler, B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 1992, 56, 622-647.
203. Van den Akker, F.; Sarfaty, S.; Twiddy, E. M.; Connell, T. D.; Holmes, R. K.; Hol, W. G. Crystal structure of a new heat-labile enterotoxin, LT-IIb. Structure 1996, 4, 665-678.
204. Nawar, H. F.; Greene, C. J.; Lee, C. H.; Mandell, L. M.; Hajishengallis, G.; Connell, T. D. LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb. Vaccine 2011, 29, 721-727.
205. Fujihashi, K.; Koga, T.; McGhee, J. R. Mucosal vaccination and immune responses in the elderly. Vaccine 2000, 18, 1675-1680.
206. Norton, E. B.; Lawson, L. B.; Freytag, L. C.; Clements, J. D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin. Vaccine Immunol. 2011, 18, 546-551.
207. Marchetti, M.; Rossi, M.; Giannelli, V.; Giuliani, M. M.; Pizza, M.; Censini, S.; Covacci, A.; Massari, P.; Pagliaccia, C.; Manetti, R.; et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998, 16, 33-37.
208. Lewis, D. J.; Huo, Z.; Barnett, S.; Kromann, I.; Giemza, R.; Galiza, E.; Woodrow, M.; Thierry-Carstensen, B.; Andersen, P.; Novicki, D.; et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4 e6999.
209. Liang, S.; Wang, M.; Triantafilou, K.; Triantafilou, M.; Nawar, H. F.; Russell, M. W.; Connell, T. D.; Hajishengallis, G. The A subunit of type IIb enterotoxin (LT-IIb) suppresses the proinflammatory potential of the B subunit and its ability to recruit and interact with TLR2. J. Immunol. 2007, 178, 4811-4819.
210. Lee, C. H.; Masso-Welch, P.; Hajishengallis, G.; Connell, T. D. TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin. J. Leukoc. Biol. 2011, 90, 911-921.
211. Martin, M.; Metzger, D. J.; Michalek, S. M.; Connell, T. D.; Russell, M. W. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Infect. Immun. 2000, 68, 281-287.
212. Mathias-Santos, C.; Rodrigues, J. F.; Sbrogio-Almeida, M. E.; Connell, T. D.; Ferreira, L. C. Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration. Clin. Vaccine Immunol. 2011, 18, 1243-1251.
213. Arce, S.; Nawar, H. F.; Russell, M. W.; Connell, T. D. Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect. Immun. 2005, 73, 2718-2727.
214. Nawar, H. F.; Berenson, C. S.; Hajishengallis, G.; Takematsu, H.; Mandell, L.; Clare, R. L.; Connell, T. D. Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I). Clin. Vaccine Immunol. 2010, 17, 969-978.
215. Greene, C. J.; Chadwick, C. M.; Mandell, L. M.; Hu, J. C.; O'Hara, J. M.; Brey, R. N., III; Mantis, N. J.; Connell, T. D. LT-IIb(T13I), a non-toxic type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity. PLoS One 2013, 8, e69678.
216. Chalifour, A.; Jeannin, P.; Gauchat, J. F.; Blaecke, A.; Malissard, M.; N'Guyen, T.; Thieblemont, N.; Delneste, Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004, 104, 1778-1783.
217. Means, T. K.; Hayashi, F.; Smith, K. D.; Aderem, A.; Luster, A. D. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. 2003, 170, 5165-5175.
218. Didierlaurent, A.; Ferrero, I.; Otten, L. A.; Dubois, B.; Reinhardt, M.; Carlsen, H.; Blomhoff, R.; Akira, S.; Kraehenbuhl, J. P.; Sirard, J. C. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J. Immunol. 2004, 172, 6922-6930.
219. McCarron, M.; Reen, D. J. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 2009, 182, 55-62.
220. Bates, J. T.; Uematsu, S.; Akira, S.; Mizel, S. B. Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J. Immunol. 2009, 182, 7539-7547.
221. Hayashi, F.; Smith, K. D.; Ozinsky, A.; Hawn, T. R.; Yi, E. C.; Goodlett, D. R.; Eng, J. K.; Akira, S.; Underhill, D. M.; Aderem, A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410, 1099-1103.
222. Liu, F.; Yang, J.; Zhang, Y.; Zhou, D.; Chen, Y.; Gai, W.; Shi, W.; Li, Q.; Tien, P.; Yan, H. Recombinant flagellins with partial deletions of the hypervariable domain lose antigenicity but not mucosal adjuvancy. Biochem. Biophys. Res. Commun. 2010, 392, 582-587.
223. Yang, J.; Zhong, M.; Zhang, Y.; Zhang, E.; Sun, Y.; Cao, Y.; Li, Y.; Zhou, D.; He, B.; Chen, Y.; et al. Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization. Hum. Vaccin. Immunother. 2013, 9, 1084-1092.
224. Vijay-Kumar, M.; Carvalho, F. A.; Aitken, J. D.; Fifadara, N. H.; Gewirtz, A. T. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur. J. Immunol. 2010, 40, 3528-3534.
225. Atif, S. M.; Uematsu, S.; Akira, S.; McSorley, S. J. CD103-CD11b+ dendritic cells regulate the sensitivity of CD4 T-cell responses to bacterial flagellin. Mucosal. Immunol. 2014, 7, 68-77.
226. Asadi Karam, M. R.; Oloomi, M.; Mahdavi, M.; Habibi, M.; Bouzari, S. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 2013, 31, 1210-1216.
227. Delaney, K. N.; Phipps, J. P.; Johnson, J. B.; Mizel, S. B. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol. 2010, 23, 201-210.
228. Weimer, E. T.; Ervin, S. E.; Wozniak, D. J.; Mizel, S. B. Immunization of young African green monkeys with OprF epitope 8-OprI-type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 2009, 27, 6762-6769.
229. Krishnan, J.; Lee, G.; Choi, S. Drugs targeting Toll-like receptors. Arch. Pharm. Res. 2009, 32, 1485-1502.